Low-dose acetylsalicylic acid and blood pressure control in drug-treated hypertensive patients

European Journal of Preventive Cardiology

Volumn 18, Issue 1, 2011, Pages 136-140

  Leinonen, Veli Matti ^a   Varis, Juha ^a   Vesalainen, Risto ^b   Päivärinta, Johanna ^a   Sillanpää, Minna ^a   Kantola, Ilkka ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Pulssi Medical Center   (Finland)

Author keywords

Acetylsalicylic acid; blood pressure control; hypertensive patients

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FINLAND; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FINLAND; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; SPHYGMOMANOMETERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959252860     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32833ace3a     Document Type: Article

References (27)

1. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993; 90: 11693–11697.
2. Howard PA, Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004; 43: 519–525.
3. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
4. Armstrong EP, Malone DC. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003; 25: 1–18.
5. Gonzáalez-Juanatey JR, Rivera J, Gabriel Sánchez R, Reviriego Almohalla B, Casimiro C. Effects of NSAID on blood pressure among hypertensive patients with a high cardiovascular risk. An Med Interna 2006; 23: 420–427.
6. Epstein M. Nonsteroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens 2002; 20(Suppl 6): S17–S23.
7. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85–95.
8. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, et al Etoricoxib Rheumatoid Arthritis Study Group. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002; 3: 10–10.
9. Jüni P, Nartey L, Riechenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–2029.
10. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481–1492.
11. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477–484.
12. Wilson SL, Poulter NR. The effect of nonsteroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertens 2006; 24: 1457–1469.
13. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
14. Hermida RC, Ayala DE, Calvo C, Lopez JE, Fernandez JR, Mojon A, et al. Administration time-dependent effects of aspirin on blood pressure in untreated hypertensive patients. Hypertension 2003; 41: 1259–1267.
15. Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, Andrade P, et al. Influence of nonsteroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995; 13: 925–931.
16. Avanzini F, Palumbo G, Alli C, Roncaglioni MC, Ronchi E, Cristofari M, et al Collaborative Group of the Primary Prevention Project (PPP) – Hypertension study. Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Am J Hypertens 2000; 13: 611–616.
17. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12: 784–789.
18. Zanchetti A, Hansson L, Dahlöf B, Julius S, Ménard J, Warnold I, et al HOT Study Group. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002; 20: 2301–2307.
19. Zhang Y, Maio Y, Whitworth JA. Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens 2007; 20: 1222–1228.
20. Taubert D, Berkels R, Grosser N, Schroder H, Grundemann D, Schomig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143: 159–165.
21. Wu R, Laplante MA, De Champlain J. Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J Hypertens 2004; 22: 793–801.
22. Ying Z, Giachini F, Tostes R, Webb R. Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation. Cardiovasc Res 2009; 83: 155–162.
23. Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens (Greenwich) 2003; 5: 53–57.
24. Markiewicz A, Semenowicz K. Time-dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm 1979; 17: 409–411.
25. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166–181.
26. Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. Eur J Cardiovasc Prev Rehabil 2006; 13: 523–528.
27. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.